Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended June 30, 2025, and provided a business and clinical update.Read More
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results
By PR Newswire
